Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells.
Cell Culture Techniques
Cell Proliferation
Cells, Cultured
Cryopreservation
/ methods
Cytokine-Induced Killer Cells
/ immunology
Cytotoxicity, Immunologic
Graft vs Host Disease
/ prevention & control
Hematopoietic Stem Cell Transplantation
Humans
Immunotherapy, Adoptive
/ methods
Interleukin-15
/ metabolism
Leukemia, Biphenotypic, Acute
/ immunology
Myelodysplastic Syndromes
/ immunology
Plasma
Transplantation, Homologous
AB-serum
CIK cells
allogeneic stem cell transplantation
cryopreservation
fresh frozen plasma
immunotherapy
platelet lysate
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
15
02
2019
accepted:
13
05
2019
entrez:
20
6
2019
pubmed:
20
6
2019
medline:
22
8
2020
Statut:
epublish
Résumé
Cytokine-induced killer (CIK) cells are an immunotherapeutic approach to combat relapse following allogeneic hematopoietic stem cell transplantation (HSCT) in acute leukemia or myelodysplastic syndrome (MDS) patients. Prompt and sequential administration of escalating cell doses improves the efficacy of CIK cell therapy without exacerbating graft vs. host disease (GVHD). This study addresses manufacturing-related issues and aimed to develop a time-, personal- and cost-saving good manufacturing process (GMP)-compliant protocol for the generation of ready-for-use therapeutic CIK cell doses starting from one unstimulated donor-derived peripheral blood (PB) or leukocytapheresis (LP) products. Culture medium with or without the addition of either AB serum, fresh frozen plasma (FFP) or platelet lysate (PL) was used for culture. Fresh and cryopreserved CIK cells were compared regarding expansion rate, viability, phenotype, and ability to inhibit leukemia growth. Cell numbers increased by a median factor of 10-fold in the presence of FFP, PL, or AB serum, whereas cultivation in FFP/PL-free or AB serum-free medium failed to promote adequate CIK cell proliferation (
Identifiants
pubmed: 31214182
doi: 10.3389/fimmu.2019.01218
pmc: PMC6554420
doi:
Substances chimiques
Interleukin-15
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1218Références
Blood. 2001 May 15;97(10):2923-31
pubmed: 11342413
Br J Haematol. 2002 Jan;116(1):78-86
pubmed: 11841399
Blood. 2004 Apr 15;103(8):3065-72
pubmed: 15070686
Exp Hematol. 2005 Jun;33(6):671-81
pubmed: 15911091
J Exp Med. 1991 Jul 1;174(1):139-49
pubmed: 1711560
Stem Cells. 2007 May;25(5):1270-8
pubmed: 17255520
Haematologica. 2007 Jul;92(7):952-9
pubmed: 17606446
Expert Opin Biol Ther. 2009 Jul;9(7):831-40
pubmed: 19463075
Haematologica. 2010 Sep;95(9):1579-86
pubmed: 20378565
Bone Marrow Transplant. 2012 Jan;47(1):73-81
pubmed: 21358682
Biol Blood Marrow Transplant. 2011 Nov;17(11):1679-87
pubmed: 21664472
Blood. 2011 Sep 22;118(12):3301-10
pubmed: 21821703
Cytotherapy. 2012 Jan;14(1):91-103
pubmed: 21973023
Bone Marrow Transplant. 2012 Jul;47(7):957-66
pubmed: 21986635
PLoS One. 2011;6(11):e27351
pubmed: 22096557
ALTEX. 2011;28(4):305-16
pubmed: 22130485
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2012 Jun;28(6):561-3
pubmed: 22691342
Bone Marrow Transplant. 2013 Aug;48(8):1141-3
pubmed: 23474803
J Immunother. 2013 Nov-Dec;36(9):462-7
pubmed: 24145357
Acta Haematol. 2014;132(1):5-9
pubmed: 24356089
Cytotherapy. 2014 Jun;16(6):835-44
pubmed: 24582456
BMC Med Genomics. 2014 Aug 09;7:49
pubmed: 25108500
J Cancer Res Clin Oncol. 2015 May;141(5):839-49
pubmed: 25381063
Ann Transl Med. 2014 Oct;2(10):97
pubmed: 25405151
Immunotherapy. 2015;7(9):999-1010
pubmed: 26310715
Transfusion. 2016 Apr;56(4):893-8
pubmed: 26661996
Haematologica. 2016 Apr;101(4):e153-6
pubmed: 26768688
Haematologica. 2016 Aug;101(8):985-94
pubmed: 27175026
Pediatr Blood Cancer. 2016 Dec;63(12):2230-2239
pubmed: 27433920
Cytotherapy. 2016 Oct;18(10):1325-31
pubmed: 27491794
J Transl Med. 2016 Sep 13;14:264
pubmed: 27620209
Cytotherapy. 2017 Mar;19(3):360-370
pubmed: 28040463
Biol Blood Marrow Transplant. 2017 Dec;23(12):2070-2078
pubmed: 28712935
Oncoimmunology. 2018 Aug 6;7(11):e1465161
pubmed: 30393581
Biol Blood Marrow Transplant. 2019 Mar 13;:null
pubmed: 30878607
J Immunol. 1994 Aug 15;153(4):1687-96
pubmed: 7519209
Cell Immunol. 1996 Apr 10;169(1):85-90
pubmed: 8612299
Blood. 1997 Oct 15;90(8):3098-105
pubmed: 9376591